See more : National Bankshares, Inc. (NKSH) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Imagi International Holdings Limited (0585.HK) Income Statement Analysis – Financial Results
- Meredith Corporation (MDP) Income Statement Analysis – Financial Results
- Sentient Brands Holdings Inc. (SNBH) Income Statement Analysis – Financial Results
- FastPartner AB (publ) (FPAR-A.ST) Income Statement Analysis – Financial Results
- PowerFleet, Inc. (PWFL) Income Statement Analysis – Financial Results
Bio-Path Holdings, Inc. (BPTH)
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44K | 43.81K | 59.45K | 79.31K |
| Cost of Revenue | 178.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 0.00 | 0.00 | 201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.11K | 37.77K | 43.88K | 55.42K |
| Gross Profit | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | -426.00K | 37.00K | 13.00K | -201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.67K | 6.05K | 15.58K | 23.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9.05% | 13.80% | 26.20% | 30.13% |
| Research & Development | 11.61M | 9.17M | 5.91M | 6.58M | 4.59M | 4.60M | 5.48M | 5.47M | 3.02M | 1.83M | 1.63M | 1.60M | 1.14M | 1.14M | 480.26K | 333.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.11M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 0.00 | 704.88K | 1.31M | 587.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 123.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.24M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 1.22M | 704.88K | 1.31M | 587.16K | 107.44K | 141.31K | 82.53K | 78.16K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 0.00 | 0.00 | 196.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.98K | 171.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 107.44K | 141.31K | 82.53K | 78.16K |
| Cost & Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 127.55K | 179.08K | 126.40K | 133.58K |
| Interest Income | 36.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 9.00K | 12.00K | 17.67K | 22.63K | 4.04K | 779.00 | 2.91K | 1.30K | 3.38K | 41.06K | 0.00 | 541.00 | 132.00 | 1.35K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.94K | 13.08K | 17.62K | 13.26K |
| Depreciation & Amortization | 82.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 411.00K | 204.00K | 201.76K | 170.91K | 160.63K | 185.27K | 211.71K | 197.27K | 182.98K | 171.95K | 1.68K | 2.72K | 3.03K | 3.06K |
| EBITDA | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | -8.16M | -8.56M | -8.27M | -5.27M | -4.35M | -3.11M | -2.40M | -2.15M | -1.88M | -1.79M | -2.68M | -107.44K | -132.00K | -63.79K | -49.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,348.65% | -76,800.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -973.44% | -301.30% | -107.30% | -62.85% |
| Operating Income | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | -8.59M | -8.97M | -8.48M | -5.48M | -4.54M | -3.27M | -2.58M | -2.37M | -2.33M | -1.97M | -2.89M | -109.11K | -135.27K | -66.95K | -54.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24,232.43% | -65,192.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% | -308.75% | -112.61% | -68.42% |
| Total Other Income/Expenses | -235.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 1.94M | 1.73M | 18.21K | 22.05K | 3.23K | -344.86K | 2.27K | -232.43K | 3.38K | 41.06K | 56.67K | -12.54K | -17.49K | -11.91K |
| Income Before Tax | -16.08M | -13.87M | -10.44M | -10.88M | -8.60M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.45K | -147.81K | -84.44K | -66.17K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.44% | -337.37% | -142.02% | -83.43% |
| Income Tax Expense | 0.00 | -33.00K | -3.00K | -26.00K | -94.00K | -608.00K | -1.94M | -1.73M | 0.00 | -22.30K | -3.23K | -142.00 | -2.27K | 232.43K | 0.00 | 2.85M | 100.00 | 100.00 | 100.00 | 100.00 |
| Net Income | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.55K | -147.91K | -84.54K | -66.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.99% | -337.60% | -142.19% | -83.56% |
| EPS | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| EPS Diluted | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| Weighted Avg Shares Out | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
| Weighted Avg Shares Out (Dil) | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Bio-Path (BPTH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Will O'Connor - Managing Director & Team Lead, Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of...
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Expands DNAbilize ® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology...
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that...
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that...
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic...
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here.
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive...
Source: https://incomestatements.info
Category: Stock Reports